<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650269</url>
  </required_header>
  <id_info>
    <org_study_id>20200793</org_study_id>
    <nct_id>NCT04650269</nct_id>
  </id_info>
  <brief_title>Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program</brief_title>
  <official_title>Implementation of Onsite, Rapid Antiretroviral Therapy (ART) Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if providing HIV medicine right away at the IDEA Syringe&#xD;
      Services Program will help the participant start and remain in HIV care, including having no&#xD;
      detectable HIV in the participant's blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with HIV viral load suppression</measure>
    <time_frame>6 months</time_frame>
    <description>HIV viral load suppression is defined as &lt;200 copies/ml in participants' blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV viral load suppression</measure>
    <time_frame>1 month</time_frame>
    <description>HIV viral load suppression is defined as &lt;200 copies/ml in participants' blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV viral load suppression</measure>
    <time_frame>12 months</time_frame>
    <description>HIV viral load suppression is defined as &lt;200 copies/ml in participants' blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Harm Reduction</condition>
  <condition>HIV Infections</condition>
  <condition>Drug Use</condition>
  <arm_group>
    <arm_group_label>Rapid ART group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive HIV care including Biktarvy for 6 months at the syringe services program followed by 6 months of standard of care at a traditional clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biktarvy 50Mg-200Mg-25Mg Tablet</intervention_name>
    <description>Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months</description>
    <arm_group_label>Rapid ART group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HIV care</intervention_name>
    <description>HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.</description>
    <arm_group_label>Rapid ART group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (age&gt;18 years);&#xD;
&#xD;
          2. positive rapid HIV test;&#xD;
&#xD;
          3. ability to provide informed consent;&#xD;
&#xD;
          4. HIV RNA &gt; 200 copies/ml;&#xD;
&#xD;
          5. creatinine clearance &gt; 30 mg/dl as measured by serum creatinine;&#xD;
&#xD;
          6. no allergy to bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) as indicated by&#xD;
             patient history and self-reported allergies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) Any other comorbidities at the discretion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>self-representation</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hansel Tookes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hansel Tookes, MD</last_name>
    <phone>3056897030</phone>
    <email>hetookes@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hansel Tookes</last_name>
      <phone>305-689-7030</phone>
      <email>hetookes@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Hansel Tookes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Hansel Tookes</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

